High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed locally recurrent prostate cancer after prior brachytherapy or external-beam radiotherapy for initial diagnosis of organ-confined disease (clinical stage T1 or T2 only)
• * Prostatic fossa biopsy positive for cancer cells
• Gleason score no greater than 7
• PSA levels 0.5-10 ng/mL
• Able to adequately visualize local recurrence on transrectal ultrasound imaging
• No prostate calcification greater than 5 mm
• No metastases by bone scan
• PATIENT CHARACTERISTICS:
• Age:
• 40 to 80
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• No bleeding disorder as determined by abnormal PT and PTT
• Renal:
• No active urinary tract infection
• No history of urinary bladder neck contracture
• Other:
• No prior allergy to latex
• No Anesthesia Surgical Assignment (ASA) category IV or greater
• No interest in future fertility
• No history of inflammatory bowel disease
• No other concurrent major nonmalignant debilitating illness
• No other prior or concurrent malignancy except skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior biologic therapy for prostate cancer
• Chemotherapy:
• No prior chemotherapy for prostate cancer
• Endocrine therapy:
• At least 3 months since prior hormonal therapy (including finasteride) for prostate cancer
• Radiotherapy:
• See Disease Characteristics
• Surgery:
• See Disease Characteristics
• No prior radical prostatectomy
• No prior transurethral resection of prostate
• No prior urethral stent
• No prior major rectal surgery
• Other:
• No prior thermotherapy
• No other prior therapy for prostate cancer
• No concurrent warfarin or other anticoagulant